Company / Operating Income
SELLAS Life Sciences Group, Inc. Operating Income History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$31.5M
FY2024
5-year range
-$37.9M / -$17.0M
FY2020-FY2024
Trend
+16.8%
vs FY2023
Sector context
#67 of 204
Health Care
What the data says
At -$32M, SELLAS Life Sciences Group, Inc.'s operating income ranks #67 of 204 in the Health Care sector. Operating Income returned to growth in FY2024 after 2 years of decline, reaching -$32M.
Based on SEC 10-K filings.
-$32M in FY2024.
Declined from -$25M to -$32M over the past 2 years.
Health Care sector context is included.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#67 of 204 in Health CareTop 33% of 204This company -$31.5M Sector average $107.7M
▼
-129.3% below sector average
Key checks
Key Insights
- In FY2024, operating income increased 16.8% year-over-year.
- Ranks #67 out of 204 companies in the Health Care sector.
- Peak operating income was recorded in FY2016.
- Lowest operating income in the period was in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -4.39 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$31.5M | +16.8% |
| FY2023 | -$37.9M | -49.7% |
| FY2022 | -$25.3M | -48.9% |
| FY2021 | -$17.0M | +0.0% |
| FY2020 | -$17.0M | +15.3% |
| FY2019 | -$20.0M | - |
| FY2018 | - | - |
| FY2017 | -$23.0M | -44.1% |
| FY2016 | -$16.0M | +53.3% |
| FY2015 | -$34.2M | +22.1% |
As of FY2024 · SEC 10-K · Updated Jun 30, 2026